Management of infectious complications in patients with acute leukemia during chemotherapy. A questionnaire analysis by the Japan Adult Leukemia Study Group

Japanese Journal of Chemotherapy

Volumn 51, Issue 11, 2003, Pages 703-710

  Yoshida, Minoru ^a   Akiyama, Nobu ^b   Takahashi, Masatomo ^c   Taguchi, Hirokuni ^d   Takeuchi, Jin ^e   Naito, Kensuke ^f   Hodohara, Yoshiko ^g   Matsushima, Takafumi ^h   Matsuda, Mitsuhiro ⁱ  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^h GUNMA UNIVERSITY   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Empiric therapy; Febrile neutropenia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARBAPENEM; CEPHEM; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; PENICILLIN G; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; FEBRILE NEUTROPENIA; HEALTH CARE ORGANIZATION; HUMAN; INFECTION PREVENTION; INFECTIOUS COMPLICATION; JAPAN; MAJOR CLINICAL STUDY; MYCOSIS; PATIENT CARE; PRACTICE GUIDELINE; QUESTIONNAIRE;

EID: 0348143387     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. De Pauw B E, Meunier F: Infections in patients with acute leukemia and lymphoma. Mandell G L, et al. (eds) Principles and practice of infectious diseases 5th edn, p.3090-3102, Churchill Livingstone Inc., New York, 2000
2. Yoshida M, Tsubaki K, Kobayashi T, et al.: Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. Int J Hematol 70: 261-267, 1999
3. Hughes W T, Armstrong D, Bodey G P, et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751, 2002
4. Ozer H, Armitage J O, Bennett C L, et al.: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558-3585, 2000
5. Murphy M E, Sepkowitz K A, Armstrong D: Prevention of infection in patients with hematologic malignancy. Wiernik P H, et al. (eds), Neoplastic Diseases of the Blood, p. 1007-1025, Churchill livingstone Inc., New York, 1996
6. Pizzo P A: Empiric therapy and prevention of infection in the immunocompromised host. Mandell G L, et al. (eds) Principles and practice of infectious diseases 5th edn, p. 3102-3112, Churchill Livingstone Inc., New York, 2000
7. Cruciani M, Rampazzo R, Malena M, et al.: Prophylaxis with Fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23: 795-805, 1996
8. Goodman J L, Winston D J, Greenfield A, et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantations. N Engl J Med 326: 845-851, 1992
9. Kanda Y, Yamamoto R, Chizuka A, et al.: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89: 1611-1625, 2000
10. Urabe A, Takaku F, Mizoguchi H, et al.: Prophylactic and therapeutic effects of oral administration of amphotericin B in mycosis associated with hematological diseases. Jpn J Antibiotics 43: 116-130, 1990
11. Pizzo P A, Hathorn J W, Hiemenz J, et al.: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552-558, 1986
12. Tamura K, Matsuoka H, Tsukada J, et al.: Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycoside : comparative study. Am J Hematol 71: 248-255, 2002
13. Viscoli C, Castagnola E, VanLint M T, et al.: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomized clinical trial. Eur J Cancer 32 A: 814-820, 1996
14. Rex J H, Walsh T J, Sobel J D, et al.: Practice guidelines for the treatment of candidiasis. Infectious diseases society of America. Clin Infect Dis 30: 662-678, 2000
15. Stevens D A, Kan V L, Judson M A, et al.: Practice guidelines for disease caused by Aspergillus. Infectious diseases society of America. Clin Infect Dis 30: 696-709, 2000
16. Lowenberg B, Touw I T: Hematopoitetic growth factors and their receptors in acute leukemia. Blood 81: 281-292, 1993
17. Maher D W, Lieschke G J, Green M, et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 121: 492-501, 1994
18. Mitchell P L, Morland B, Stevens M C, et al.: Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 15: 1163-1170, 1997
19. Yoshida M, Karasawa M, Naruse T, et al.: Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Int J Hematol 69: 81-88, 1999
20. Masaoka T: Evidence-based recommendations on antimicrobial use in febrile neutropenia in Japan. Int J Hematol 68 (suppl 1): 1-40, 1998